Advanced Search
Therapeutic Area Disease
Title Drug Phase
Clinical Trials Listing
Active treatment trials at Penn's Abramson Cancer Center
Protocol ID Title Phase Modality Drug
RTOG 1308 Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC III Chemotherapy, Radiotherapy, Proton Therapy carboplatin; cisplatin; etoposide; paclitaxel
CALGB-30610 Phase III Comparison of Thoracic Radiotherapy Regimens in Patients With Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide III Chemotherapy, Radiotherapy cisplatin; etoposide
UPCC-11511 An Open-label, Randomized, Phase IIIb Trial Evaluating the Efficacy and Safety of Standard of Care +/- Continuous Bevacizumab Treatment Beyond Progression of Disease (PD) in Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) After First (1st)-Line Treatment With Bevacizumab Plus a Platinum Doublet-containing Chemotherapy III Angiogenesis Inhibitor, Immunotherapy (Monoclonal Antibody) bevacizumab
3475-010 A Phase II/III Randomized Trial of Two Doses of MK-3475 (SCH900475) Versus Docetaxel in Previously Treated Subjects With Non-Small Cell Lung Cancer II / III Chemotherapy docetaxel; pembrolizumab
UPCC-18512 Phase 2 Study of Etirinotecan Pegol (NKTR-102) in the Treatment of Patients With Metastatic and Recurrent Non-Small Cell Lung Cancer (NSCLC) After Failure of 2nd Line Treatment II Topoisomerase Inhibitor etirinotecan pegol
UPCC 05513 GSK2302032A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer II Immunotherapy GSK2302032A
UPCC-24213 A Phase Ib/II Clinical Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies I / II Chemotherapy, Signal Transduction Inhibitor paclitaxel; BBI608
UPCC-25508 Feasibility and PhaseI/II Trial of Preoperative Proton Beam Radiotherapy With Concurrent Chemotherapy for Resectable Stage IIIA or Superior Sulcus NSCLC I / II Chemotherapy, Surgery, Proton Therapy cisplatin; etoposide
NCI-2012-01985 Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer I / II Chemotherapy, PARP Inhibitor cisplatin; etoposide; veliparib
UPCC-13514 A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Solid Tumors (Phase 1) Followed by a Randomized, Double-Blind, Placebo-Controlled Study in Subjects With Advanced NSCLC (Phase 2)(INCB 24360-202 / MK-3475-037 / KEYNOTE-037) I / II Immunotherapy, Signal Transduction Inhibitor INCB024360; pembrolizumab
CO-1686-008 A Phase 1/2, Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of Oral CO-1686 in Patients With Previously Treated Mutant EGFR Non-Small Cell Lung Cancer (NSCLC) I / II Signal Transduction Inhibitor Rociletinib
CO-338-010 A Phase I/II, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Oral Rucaparib in Patients With gBRCA Mutation Breast or Ovarian Cancer, or Other Solid Tumor I / II PARP Inhibitor rucaparib
UPPC-20512 A Phase I Study of Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion I Gene Therapy Adenovirus (Adv)-mediated thymidine kinase ; valacyclovir
UPCC-29212 A Phase I/II Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers I Signal Transduction Inhibitor GSK525762
UPCC-08314 Pilot Study of HPV Specific Immunotherapy in Subjects With HPV6 Associated Aerodigestive Malignancies I Immunotherapy INO-9012; INO-3106
UPCC-05511 A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer I Immunotherapy MGA271
UPCC 19913 A Phase 1, Open-Label, Multicenter, Dose Escalation Study to Assess the Safety and Tolerability of MLN7243, an Inhibitor of Ubiquitin-Activating Enzyme (UAE), in Adult Patients With Advanced Solid Tumors I Signal Transduction Inhibitor MLN7243
UPCC-11510 A Phase 1, Open-Label, Single Center Study of the Imaging Potential of Indocyanine Green in Subjects Undergoing Thoracic Surgery Presenting With Lung Nodules I Imaging Procedure Indocyanine Green
UPCC 12512 The Detection Of Circulating Tumor Cells (CTC) In Patients With Non-small Cell Lung Cancer (NSCLC) Undergoing Definitive Radiotherapy Or Chemoradiotherapy Not Specified Radiation Therapy Not Applicable
UPCC-23309 Retreatment of Recurrent Tumors Using Proton Therapy Not Specified Proton Therapy Not Applicable
UPCC 08909 A Volume, Motion, and Anatomically Adaptive Approach to Photon and Proton Beam Radiotherapy Not Specified Not Applicable
Active non-treatment trials at Penn's Abramson Cancer Center
Protocol ID Title Phase Modality Drug
UPCC-05912 Extended Duration Varenicline for Smoking Among Cancer Patients: A Clinical Trial III Other, Supportive Care varenicline tartrate
AT005074 Long-Term Chamomile Therapy for Generalized Anxiety Disorder (GAD) III Supportive Care Not Applicable
UPCC-11111 A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex® Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy III Supportive Care GW-1000-02 (Sativex)
UPCC-14111 A Multicenter, Non-comparative, Open-label Extension Study to Assess the Long Term Safety of Sativex® Oromucosal Spray (Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer-related Pain III Other GW-1000-02 (Sativex)
UPCC 11513 Acupuncture Feasibility Trial for Dyspnea in Lung Cancer I Supportive Care Not Applicable
UPCC 01914 Patient-Centered Integration of Acupuncture to Decrease Pain for Cancer Survivors Not Specified Pain Management Not Applicable
UPCC-12807 Assessing Fertility Potential in Female Cancer Survivors Not Specified Imaging Procedure, Blood Test Not Applicable
Active advanced solid tumor trials at Penn's Abramson Cancer Center
Protocol ID Title Phase Modality Drug
UPCC-07913 A Phase 1b, Open-Label, Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Patients With Solid Tumors I Chemotherapy, Signal Transduction Inhibitor docetaxel; carboplatin; gemcitabine; paclitaxel; MLN4924
3475-028 Phase IB Study of MK-3475 in Subjects With Select Advanced Solid Tumors I Immunotherapy, Signal Transduction Inhibitor pembrolizumab
UPCC-06914 A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients With Advanced and/or Treatment-Refractory Solid Tumors I Signal Transduction Inhibitor CB-839
UPCC-05314 A Phase 1a/1b Study of the Oral TRK Inhibitor LOXO-101 in Subjects With Adult Solid Tumors I Signal Transduction Inhibitor LOXO-101
Active proton therapy trials at Penn's Abramson Cancer Center
Protocol ID Title Phase Modality Drug
RTOG 1308 Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC III Chemotherapy, Radiotherapy, Proton Therapy carboplatin; cisplatin; etoposide; paclitaxel
UPCC-25508 Feasibility and PhaseI/II Trial of Preoperative Proton Beam Radiotherapy With Concurrent Chemotherapy for Resectable Stage IIIA or Superior Sulcus NSCLC I / II Chemotherapy, Surgery, Proton Therapy cisplatin; etoposide
UPCC-23309 Retreatment of Recurrent Tumors Using Proton Therapy Not Specified Proton Therapy Not Applicable

Request a call

A clinical trial navigator is available to help you search for clinical trials offered by the Penn Medicine Abramson Cancer Center. This is a confidential free service available Monday-Friday, 9:00am-5:00pm (ET). Requests are processed in the order they are received.



*
*
*
*

Please do not submit another person’s name or email without his or her consent.